Longevity frontiers & research watchlist

Research peptides, experimental rejuvenation, exercise mimetics and clinic treatments — made findable without implying approval, proven efficacy or endorsement.

Research Peptides Library

Peptides sold through clinics and research-chemical channels, separated from approved medical uses and actual human evidence.

• BPC-157 — A synthetic peptide promoted for tendon, gut and injury healing despite the absence of a defensible human longevity evidence base. (safety-priority)
• TB-500 — A thymosin-β4 fragment marketed for recovery and tissue repair, often stacked with BPC-157. (safety-priority)
• Epitalon — A tetrapeptide promoted with telomere, sleep and lifespan claims that run far ahead of reliable human evidence. (research-only)
• Growth-hormone secretagogues — A mixed class spanning approved disease-specific treatments, investigational drugs and unapproved clinic stacks. (safety-priority)
• Mitochondrial-derived peptides — Mitochondrial signalling peptides and targeted compounds with real scientific interest but very different stages of clinical development. (early-human)
• Other experimental peptides — A searchable holding page for peptide names already circulating before each warrants a full independent synthesis. (research-only)

Experimental Rejuvenation

Serious frontier science, commercial rejuvenation claims and the large gap between them.

• Partial cellular reprogramming — Transient reprogramming aims to shift aged cells towards a younger state without erasing cell identity. (research-only)
• Plasma interventions — Young-donor plasma, therapeutic plasma exchange and experimental plasma dilution are distinct interventions that marketing often collapses into one story. (safety-priority)
• Exosomes & stem-cell infusions — Legitimate regenerative-medicine research is routinely used to market unapproved infusions with broad rejuvenation claims. (safety-priority)

Exercise Mimetics & Metabolic Compounds

Compounds claimed to mimic exercise, alter fuel use or slow biological ageing — without confusing a pathway with an outcome.

• AICAR — An experimental metabolic compound used to study AMPK — not “exercise in a pill” and not a proven longevity treatment. (research-only)
• Next-generation exercise mimetics — Preclinical compounds intended to alter energy expenditure or reproduce selected molecular responses to exercise. (research-only)
• Emerging metabolites & supplements — A mixed evidence set: some compounds have early human trials, others mostly biomarker, mechanistic or observational support. (early-human)

Clinic Treatments Under the Microscope

High-cost treatments appraised by indication, evidence, risk and the claims actually made to healthy customers.

• Ozone therapy & EBOO — Blood-exposure procedures marketed as detoxification, oxygenation or mitochondrial optimisation without established longevity benefit. (safety-priority)
• Oxygen, light & electromagnetic treatments — Modalities with plausible biology and some defined uses, frequently extended into whole-body longevity promises. (mixed)
• Neuromodulation & whole-body cold — Approved implanted neuromodulation, consumer vagus gadgets and whole-body cryotherapy should not share one evidence label. (mixed)
• Molecular hydrogen — Small short studies report biomarker signals, but established clinical or longevity outcomes are absent. (early-human)

Research watchlist

Terms we actively monitor before a full appraisal is justified.